Dyslipidemia in Chronic Kidney Disease: Managing a High-Risk Combination

@article{Chauhan2009DyslipidemiaIC,
  title={Dyslipidemia in Chronic Kidney Disease: Managing a High-Risk Combination},
  author={V. Chauhan and M. Vaid},
  journal={Postgraduate Medicine},
  year={2009},
  volume={121},
  pages={54 - 61}
}
Abstract Cardiovascular disease (CVD) is the single largest cause of mortality in patients with chronic kidney disease (CKD), with those patients having a 10-year CVD-related morbidity and mortality of > 20%. This has led to the inclusion of CKD as a CVD equivalent, and justifies the aggressive treatment of modifiable risk factors such as dyslipidemia. Primary care physicians (PCP) often manage patients with CKD in the early stages of the disease and have a pivotal role in affecting long-term… Expand
Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease
TLDR
Lifestyle modifications, including weight control, cessation of smoking and dietary salt restriction, are measures that should have a major impact in the cardiovascular morbidity and mortality in patients with CKD. Expand
Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients
TLDR
The introduction of diet change was shown to exert beneficial effect on the lipid level lowering that reaches beyond pharmacological therapy, and currently available data on dietary interventions in CKD patients is of low quality. Expand
A study of lipid profile and ECG changes in chronic kidney disease patients
Introduction: Hyperlipidemia, one of the important risk factor of atherosclerosis, is an abnormality commonly encountered in patients with chronic kidney disease. There are several other importantExpand
Mediterranean diet improves dyslipidemia and biomarkers in chronic renal failure patients.
TLDR
It is demonstrated that the nutritional management of CRF patients before dialysis based on the MD improves food consumption, reduces dyslipidemia and protects against lipid peroxidation and inflammation, allowing patients to enter dialysis with an acceptable nutritional and cardiovascular state. Expand
Prevalence of Dyslipidemia in None Diabetic Sudanese Patients with End Stage Renal Disease on Regular Hemodialysis
Dyslipidemia is considered as one of the major risk factors for cardiovascular disease (CVD) in general population. This study was conducted to identify the prevalence of disturbance of lipidExpand
Current Concepts and Management Strategies in Chronic Kidney Disease-Mineral and Bone Disorder
TLDR
CKD-mineral and bone disorder is a broader, newly defined term that should be used instead of renal osteodystrophy to define the mineral, bone, hormonal, and calcific cardiovascular abnormalities that are seen in CKD. Expand
Effect of High Flux Versus Low Flux Hemodialysis on Some Cardiovascular Risk Factors in Egyptian Children with End Stage Renal Disease.
TLDR
Improvement of some markers of dyslipidemia and inflammation by using high-flux HD in children with ESRD is demonstrated for the first time, suggesting that high- flux dialysis may benefit such young suffering population by reducing the atherogenic risk, cardiovascular morbidity and mortality. Expand
Contribution of High Flux Membranes to the Therapy of Uremia‐Associated Dyslipidemia
  • A. Azak, B. Huddam, +4 authors M. Duranay
  • Medicine
  • Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2012
TLDR
The results show that high‐flux dialyzers improved dyslipidemia and endothelial dysfunction in hemodialysis patients, providing a new insight on the selection of high efflux in he modialysis. Expand
The Evolving Understanding of the Contribution of Lipid Metabolism to Diabetic Kidney Disease
TLDR
Enhanced fatty acid oxidation in the kidney induced by fenofibrate, a peroxisomal proliferator-activated receptor (PPAR)-α agonist, showed benefit in mouse models of CKD, suggesting that further understanding of lipid metabolism in diabetic kidney disease may lead to novel therapeutic approaches. Expand
Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status
TLDR
The study shows that a treatment with reduced fenofibrate dose is safe and effective in reducing serum triglycerides and cholesterol in chronic dialysis patients and may shift plasma aminothiol balance towards a more antioxidative pattern. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 51 REFERENCES
Managing dyslipidemia in chronic kidney disease
TLDR
Current guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative recommend aggressive therapy of dyslipidemia, and there is suggestive evidence that statin therapy, in particular, also may reduce inflammation and slow the decline in glomerular filtration rate in patients during the earlier stages of CKD. Expand
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
  • B. Kasiske, F. Cosio, +9 authors P. Wilson
  • Medicine
  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2004
TLDR
These guidelines, which are a modified version of the K/DOQI dyslipidemia guidelines, were developed to aid clinicians in the management of dyslipidemias in kidney transplant patients and are supported mainly by data from studies in the general population but there is an urgent need for additional studies in CKD and in transplant patients. Expand
A quick guide to evidence-based chronic kidney disease care for the primary care physician.
TLDR
This article synthesizes the key evidence-based behaviors and clinical action plan that primary care physicians can implement to treat CKD and its complications. Expand
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
TLDR
In hypertensive patients with moderate dyslipidemia and decreased eGFR, pravastatin was not superior to usual care in preventing clinical renal outcomes, however, benefit from statin therapy may depend on the degree of the cholesterol level decrease achieved. Expand
Study of Heart and Renal Protection (SHARP).
TLDR
The Study of Heart and Renal Protection (SHARP) aims to assess the effects of cholesterol-lowering therapy with a combination of simvastatin and the cholesterol-absorption inhibitor ezetimide among around 9000 patients with CKD. Expand
Pravastatin for Secondary Prevention of Cardiovascular Events in Persons with Mild Chronic Renal Insufficiency
TLDR
A subgroup analysis of a large randomized, double-blind, placebo-controlled trial shows that pravastatin reduces risk for future cardiovascular events in men and women with recent myocardial infarction, total cholesterol level less than 6.21 mmol/L, and mild renal insufficiency. Expand
Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition
TLDR
The inverse association of total cholesterol level with mortality in dialysis patients is likely due to the cholesterol-lowering effect of systemic inflammation and malnutrition, not to a protective effect of high cholesterol concentrations. Expand
Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.
TLDR
The results indicate that the rapidly developing atherosclerosis in advanced CRF appears to be caused by a synergism of different mechanisms, such as malnutrition, inflammation, oxidative stress, and genetic components. Expand
Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome.
TLDR
Lower lipid levels are associated with higher mortality in patients who have moderate and advanced CKD and are not yet on dialysis, explained in part by case-mix characteristics and the presence of surrogates for MICS. Expand
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
TLDR
Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis. Expand
...
1
2
3
4
5
...